Real-world Study of Dedifferentiated Liposarcoma Patients in China

Boehringer Ingelheim

Status: Completed

Conditions: Dedifferentiated Liposarcoma

Study type: Observational

Funder types: Industry

Identifiers

NCT06115681

1403-0024

Details and patient eligibility

About

This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.

Enrollment: 1,390 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

• Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013.
• Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime.
• At least 18 years old at the date of initial diagnosis.

No exclusion criteria are applied.

Trial design

1,390 participants in 2 patient groups

DDLPS patients with 1L treatment at index date (Cohort 1)

Description:

Patients with unresectable locally advanced or metastatic differentiated liposarcoma (DDLPS) who received at least one line of systemic antineoplastic treatment by the end of cohort identification period (index date = start date of first line (1L) treatment).

DDLPS patients without 1L treatment at index date (Cohort 2)

Description:

Patients with DDLPS who have not initiated 1L systemic antineoplastic treatment by the end of cohort identification period (index date = date of initial DDLPS diagnosis during cohort identification period). Patients who initiated 1L treatment afterwards or patients who received adjuvant and/or neoadjuvant therapy only through follow-up were included in Cohort 2.